| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
– Approval triggers $10 million cash milestone payment to Verrica –
– YCANTH® approval in Japan addresses significant unmet need of patients with molluscum –
– Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan –
WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that its development partner, Torii Pharmaceutical Co. Ltd. ("Torii") has received approval from the Japanese Ministry of Health, Labour and Welfare ("MHLW") for YCANTH® (TO-208) for the treatment of Molluscum Contagiosum ("molluscum"). Torii became a wholly-owned subsidiary of Shionogi & Co., Ltd., on September 1, 2025.
Posted In: VRCA
